Highlights in early breast cancer from the ASCO 2020 Virtual Meeting are discussed by Dr Harold Burstein of Dana-Farber Cancer Institute.
Two studies in HER2-positive breast cancer provided data on refining adjuvant regimens. The KAITLIN trial compared a three-drug regimen of anthracycline, TDM-1, and pertuzumab with a four-drug regimen of anthracycline, trastuzumab, taxane, and pertuzumab, seeking to determine whether the addition of TDM-1 would improve long-term outcomes. The study showed no benefit from TDM-1; outcomes were identical for both groups.
The TRAIN-2 study asked whether anthracycline-based chemotherapy can safely be omitted in early-stage breast cancer. Results suggest that the answer is yes. Dr Burstein notes that omitting anthracyclines may also lower risk for cardiac damage.
Key ER-positive studies included long-term follow-up of the MINDACT trial, which used the 70-gene MammaPrint assay to stratify patients. The study showed that adding chemotherapy to endocrine therapy provided no benefit in patients identified as having high-risk clinical scores but low-risk genomic scores.
Finally, among triple-negative presentations, a large trial from China demonstrated that the use of so-called metronomic doses (1000 mg twice a day) of adjuvant capecitabine provided improved disease-free survival and a trend favoring overall survival.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Early Breast Cancer Highlights From ASCO 2020 - Medscape - Jun 24, 2020.
Comments